Niemann-Pick type C1-like 1 (NPC1L1) protein is responsible for intestinal cholesterol absorption. The aim of the study was to identify genetic polymorphisms of the NPC1L1 gene as well as their functional significance. The method involved screening of promoter and coding regions of the NPC1L1 gene for genetic polymorphisms by direct DNA sequencing of genomic DNA from 50 individuals. Functional studies on promoter polymorphisms were performed using luciferase assay. Association between the polymorphisms and serum cholesterol levels were investigated in 224 individuals. The results showed that in total, 11 single nucleotide polymorphisms were identified. Among them, a promoter polymorphism, g.À762T4C, and a synonymous polymorphism, g.1679C4G, were common (34 and 36%, respectively). These two polymorphisms were highly linked (D¢ value¼0.7459, P-value o0.00001). For the g.À762T4C promoter polymorphism, luciferase assay in HepG2 cell line demonstrated that the À762C allele had a significantly higher promoter activity than the À762T allele (1.30 ± 0.22 vs 0.37 ± 0.06, 3.5-fold, Po0.05). We also showed that the NPC1L1 promoter activity was downregulated by cholesterol content in both genotypes. When association studies were performed, we found that À762C allele was associated with significantly higher serum total cholesterol and LDL-cholesterol content levels in a recessive model (LDL-cholesterol value¼131.2 ± 8.1 vs 116.4 ± 2.2 mg dl -1 ; total cholesterol value¼214.7 ± 9.0 mg dl -1 vs 196.9 ± 2.6, P-value o0.05, n¼224). In conclusion, the C allele at À762 position of the NPC1L1 gene was common in people of Chinese ethnicity. The À762C allele had a higher promoter activity and was associated with a higher serum total cholesterol and LDL-cholesterol level.
INTRODUCTION
Cardiovascular disease is a worldwide problem and hypercholesterolemia contributes to cardiovascular diseases by promoting atherosclerosis. 1 Cholesterol homeostasis in the human body is tightly regulated through dietary cholesterol absorption, biliary secretion and de novo synthesis. There are variations in serum cholesterol levels and inter-individual variations in cholesterol absorption rates might be a possible reason. It has been reported that cholesterol absorption is influenced by several factors, such as dietary composition, age and genetic factors.
Recently, the Niemann-Pick type C1-like 1 protein (NPC1L1) was identified as an intestinal cholesterol transporter. [2] [3] [4] [5] [6] [7] [8] It is also the molecule target for the new cholesterol-lowering agent, ezetimibe. 9 Human NPC1L1 is expressed mainly in the intestine and liver and is responsible for transporting cholesterol from intestinal lumen to enterocytes. It is now believed that intestinal cholesterol absorption is regulated by two transporters, NPC1L1 and ABCG5/8. 10,11 ABCG5/ 8 is a heterodimer transporter and may be responsible for selective reverse cholesterol transport from the enterocytes to the intestinal lumen. Several genetic variations in ABCG5/8 have been identified to cause sitosterolemia, a rare disorder characterized by increased serum sitosterol levels. [12] [13] [14] [15] However, there are a limited number of studies that focus on the effects of NPC1L1 genetic variation. Therefore, the aim of this study was to identify genetic variations of NPC1L1 and to investigate whether these variations are associated with variations in serum cholesterol levels.
MATERIALS AND METHODS

Study subjects
A total of 224 consecutive individuals undergoing health check-ups at the National Taiwan University hospital were included in the study. Serum levels of total cholesterol, triglyceride, low-density lipoprotein (LDL)-cholesterol and high-density lipoprotein-cholesterol were determined independently. The demographic data and serum cholesterol profiles are shown in Table 1 .
Detection of genetic polymorphisms and genotyping
We screened the promoter and coding regions of the NPC1L1 gene for genetic polymorphisms by direct DNA sequencing of genomic DNA from 50 individuals. Total cellular DNA was isolated from peripheral blood lymphocytes using a PureGene genomic DNA purification kit (Gentra Systems Inc., Valencia, CA, USA). The promoter (from À971 to +1 bp) and coding regions of the NPC1L1 gene were amplified using PCR. The base sequence of the primer pairs is shown in Table 2 . PCR was performed with an initial denaturation step of 95 1C for 5 min, followed by 35 cycles of denaturation at 95 1C for 30 s, annealing at 55 1C for 30 s and extension at 72 1C for 30 s. A final elongation step was performed at 72 1C for 10 min. DNA sequencing was performed using an automated sequence analyzer. Further genotyping was performed on the 224 individuals using PCR and direct DNA sequencing.
Plasmid construction
The promoter region between À1405 and +52 bp of the human NPC1L1 gene was amplified using human genomic DNA as the template. KpnI and BglII restriction sites were introduced into the forward and reverse primers, respectively, to facilitate subsequent cloning work. The forward primer was: 5¢-CAGGTACCGGCTCATTCCCCATTCACCGACTGC (underline indicates KpnI cutting site) and the reverse primer was: 5¢-GTAGATCTAGCGCAGGAG CAGGGCCCACAGCAG (underline indicates BglII cutting site). The PCR product was then digested with KpnI and BglII enzymes and inserted into a luciferase gene control vector, pGL3 basic vector (Promega, Madison, WI, USA). All constructs were confirmed by DNA sequence.
Cell culture and transient transfection
HepG2 cells were cultured in Dulbecco's modified Eagle's medium containing 2 mM L-glutamine, 1.5 g l -1 sodium bicarbonate, 100 mM non-essential amino acids, 1.0 mM sodium pyruvate and supplemented with 10% fetal bovine serum at 37 1C with 5% CO 2 .
For transfection studies, HepG2 cells were plated onto 96-well plate (8Â10 4 cells per well) before 24-h transfection. 16 The cells were transiently cotransfected with 250 ng of pGL3 basic luciferase vector, pGL-762T or pGL-762C constructs, and 25 ng pRL-TK vector (Renilla luciferase-bearing vector) using jetPEI transfection reagent according to the manufacturer's instructions. In all transfections, pRL-TK vector (Renilla luciferase-bearing vector-Promega) served as an internal control to normalize the efficiency of transfection. After 24-h transfection, the cells were washed with phosphate-buffered saline solution and incubated for an additional 24 h in either fresh medium, 40 mM of lovastatin, 10 mg ml -1 or 20 mg ml -1 cholesterol (Sigma, St Louis, MO, USA), and 5 or 15 mM of ezetimibe (Schering-Plough/Merck, Kenilworth, NJ, USA). 17 Finally, luciferase assay was performed using the Dual-GloLuciferase Reporter Assay System according to the manufacturer's instructions (Promega).
Statistical analysis
Data were expressed as mean ± s.e.m. Parametric data between groups were compared using the Student's t-test. A P-value of less than 0.05 was considered statistically significant. Linkage disequilibrium and haplotype analyses were 
RESULTS
Identification of NPC1L1 polymorphisms
To detect genetic polymorphisms of the NPC1L1 gene, genomic DNA from 50 individuals (100 chromosomes) were analyzed. In total, 11 single nucleotide polymorphisms (SNPs) were identified. Among these, five were in the NPC1L1 coding region, with two causing amino-acid changes (P282T and A1238V). For the remaining six SNPs, four were intronic SNPs, and two located in the promoter region. The allele frequencies of the SNPs are shown in Table 3 . Among the 11 SNPs, g.À762T4C (ss119336593) and g.1679C4G (rs2072183) were common and the frequencies of the minor allele were 34 and 36%, respectively. In addition, our results revealed that the two common SNPs, g.À762T4C and g.1679C4G, were highly linked (D¢ value¼0.7459, P-value o0.00001) ( Table 4) .
Promoter assay for NPC1L1 promoter SNP As to the two common SNPs, g.À762T4C was in the promoter region and g.1679C4G was synonymous, we therefore performed luciferase assay to assess whether g.À762T4C contributed to variations in the promoter activity of the NPC1L1 gene. We cloned two promoter constructs (pGL-762T and pGL-762C), and transient transfection into HepG2 cells was performed. In luciferase assays, both of the promoter constructs (pGL-762T and pGL-762C) showed a significant increase in promoter activity compared with the pGL3 basic vector without NPC1L1 promoter region (3.1-fold, P-value¼0.0278 and 10.8-fold, P-value¼0.0001, respectively) ( Figure 1 ). In addition, the pGL-762C construct showed significantly higher promoter activity than that of pGL-762T construct (3.5-fold, P-value¼0.00157), suggesting that the minor C allele may contribute to increase NPC1L1 transcript production (Figure 1 ).
Effect of added cholesterol, lovastatin and ezetimibe on the promoter activity of NPC1L1 We further investigated whether the À762T and À762C differed in their response to cholesterol, lovastatin (a cholesterol synthesis inhibitor) as well as ezetimibe (an intestinal cholesterol absorption inhibitor). When HepG2 cells were incubated with cholesterol at 10 mg ml -1 , the promoter activity of constructs, pGL-762T and pGL-762C, decreased slightly (0.95-and 0.82-fold, respectively). Furthermore, when cells were treated with higher cholesterol contents (20 mg ml -1 ), the promoter activity of both pGL-762T and pGL-762C constructs declined significantly (0.78-and 0.65-fold, respectively). This result suggested that the inhibitory effect of cholesterol was dose dependent. In contrast, when lovastatin was added, the promoter activity showed a significant increase (2.17-fold for pGL-762T and 1.76-fold for pGL-762C), demonstrating that the promoter activity of NPC1L1 was regulated by cholesterol level. However, when cells were treated with either lovastatin (40 mM) or cholesterol (20 mg ml -1 ), the promoter activity of pGL-762C construct was still significantly higher than that of pGL-762T (2.8-fold, P-value¼0.04545, n¼5-6 for treatment lovastatin; 2.9-fold, P-value¼0.00003, n¼4-6 for treatment cholesterol) (Figure 1) .
We further investigated the response of the two promoter constructs to ezetimibe. Although cells were incubated with 5 mM of ezetimibe, the promoter activity of pGL-762T and pGL-762C dropped by 0.79-and 0.89-fold, respectively, respectively). At a higher concentration of ezetimibe (15 mM), the promoter activity further declined (0.70-and 0.69-fold of basal level, respectively). These results demonstrated that the inhibitory effect of ezetimibe on the NPC1L1 promoter activity was dose dependent (R 2 ¼0.3683, P-value¼0.0164 for pGL-762T and Table 3 The NPC1L1 SNPs and their allele frequencies identified in 50 subjects Relative Luciferase Activity Figure 1 Effect of exogenous cholesterol or lovastatin on the Niemann-Pick type C1-like 1 (NPC1L1) promoter activity. pGL-762T and pGL-762C indicate À762T and À762C promoter constructs, respectively. pGL3 basic represents a negative control vector, which does not have a NPC1L1 promoter sequence. HepG2 cells were transiently transfected with the promoter constructs. pGL-762C had a significantly higher promoter activity than pGL-762T (Po0.005). Supplementing with cholesterol (10 or 20 mg ml -1 ) decreased NPC1L1 promoter activity, while adding lovastatin (40 mM) increased promoter activity. Data are means±s.e.m. (n¼B3-6).
R 2 ¼0.3201, P-value¼0.035 for pGL-762C by linear regression). When comparing the two promoter constructs, the promoter activity of pGL-762C construct was significantly higher than that of pGL-762T at both ezetimibe concentrations (Figure 2 ).
Association between NPC1L1 polymorphisms and serum cholesterol levels For analysis of association between NPC1L1 SNP and cholesterol levels, only SNPs with a frequency of 45% were used. HardyWeinberg equilibrium was tested for g.À762T4C and g.1679C4G.
Both did not significantly violate the Hardy-Weinberg equilibrium (P-value¼0.0687 and 0.1834 in the w 2 test). Tables 5 and 6 show the results of association analysis of serum cholesterol levels and genotypes for SNP g.À762T4C and g.1679C4G, respectively. This demonstrated that the genotype of g.À762T4C was significantly associated with serum total cholesterol and LDP-cholesterol level in a recessive genetic model (P-value¼0.0477 and 0.0494, n¼224), but was not associated with triglyceride and high-density lipoprotein-cholesterol level. The minor allele (g.À762T4C) had a frequency of 34.1% (n¼153/448), and individuals with homozygous À762C allele had 9.0% higher serum total cholesterol and 12.7% higher serum LDL-C, respectively (total cholesterol value¼214.7±9.0 vs 196.9 ± 2.6 mg dl -1 , P-value¼0.0477; LDL-cholesterol value¼131.2 ± 8.1 vs 116.4 ± 2.2 mg dl -1 , P-value¼0.0494) (Figure 3 ). If we divided the patients into normocholesterolemic (total cholesterol o240 mg dl -1 ) and hypercholesterolemic (total cholesterol o240 mg dl -1 ) groups, the genotype distribution of g.À762T4C differed significantly between the two groups ( Table 7) . On the other hand, the genotype distribution of g.1679C4G did not differ significantly between the two groups ( Table 7) . We also analyzed the genotype distributions of both polymorphisms by using 200 mg dl -1 as the cholesterol cutoff value. We found that there were no significant differences in the genotype distributions in both polymorphisms. 20 on the other hand, demonstrated that rare non-synonymous SNPs of the NPC1L1 gene were associated with baseline plasma LDLcholesterol levels. However, the incidences of these SNPs were extremely low. In this study, we demonstrated that the allele frequencies of the NPC1L1 polymorphisms in people of Chinese ethnicity were quite different from those reported in Western countries. For instance, g.À762T4C polymorphism was common in Chinese with a minor allele frequency of 34.1% in this, whereas its frequency is extremely low (o1%) in Caucasians as reported by Simon et al. On the other hand, SNP g.À18C4A is common in Western reports, but was absent in the 50 individuals of our study. For another common SNP, g.1679C4G (L272L), the minor allele frequency was similar (30-40%) among our study and previous reports.
Functional studies were performed for the promoter polymorphism (g.À762T4C) and we demonstrated that the minor allele contributed to a higher promoter activity. We also showed that the minor allele was associated with higher serum cholesterol levels. Theoretically, variations in NPC1L1 transcript amount might be related to variations in baseline cholesterol levels. In NPC1L1 knockout mice, intestinal cholesterol absorption decreased by 69%. In humans, Miettinen and Kesaniemi 21 reported that lower cholesterol absorption was associated with lower serum levels of cholesterol. It is therefore reasonable that variations in promoter activity might be related to changes in serum cholesterol levels.
Our functional analysis of the NPC1L1g.À762T4C polymorphism suggested that homozygous carriers of the minor allele of g.À762T4C might have more NPC1L1 gene expression in enterocytes, leading to an increase in cholesterol absorption. We also demonstrated that NPC1L1 promoter activity was regulated by cholesterol concentration, suggesting that NPC1L1 promoter regulation was similar to other cholesterol metabolism genes, such as HMG-CoA reductase, LDL receptor and high-density lipoprotein receptor. [22] [23] [24] Besides, our results were consistent with data reported by other group, NPC1L1 transcription activity was inhibited while cells were treated with ezetimibe. 25 In addition, it has been reported that NPC1L1 promoter is regulated mainly by SREBP-2, a transcription factor-regulated cholesterol metabolism-related genes expression. 17 Both putative sterol regulatory elements and Ying Yang-1 (YY1)-binding sites are present in the promoter region of NPC1L1, suggesting that these transcription factors may regulate the NPC1L1 gene expression. 26 Alrefai et al. 17 also demonstrate that there are two putative sterol regulatory elements (BÀ657 to À648 and BÀ35-to À26 bp) within human NPC1L1 promoters. YY1 has been proved to be a negative regulator of SREBP-dependent genes. [27] [28] [29] However, it is still unknown whether YY1 also participates in regulating NPC1L1 expression. According to a report by Davies et al., there are two putative YY1 conserved binding sites located in the promoter (BÀ771 to À752 bp) and coding region (BÀ10 to +11 bp) of the NPC1L1 gene. The consensus sequence of the YY1 binding site is 5¢-CCAT-3¢ or 5¢-ACAT-3¢. The g.À762T4C polymorphism is located in the YY1 conserved binding sites in the promoter region. The minor allele might cause a reduction of YY1's DNA-binding activity, reducing the transcription inhibition effect of YY1 and leading to an increase in NPC1L1 transcripts.
In summary, our studies showed that SNP g.À762T4C is significantly associated with serum total cholesterol and LDL-cholesterol levels. This was consistent with our finding that the minor allele promoter construct (g.À762T4C) showed significantly higher promoter activity than the major allele construct. These results suggest that homozygous carriers of the minor allele of g.À762T4C might have more NPC1L1 expression in enterocytes, and therefore leads to increased cholesterol absorption. However, it is still unclear whether g.À762T4C is associated with hypercholesterolemia-related diseases (for example, atherosclerosis), and this needs to be further investigated.
